Acumen licenses Halozyme ENHANZE tech for subcutaneous ACU193; seven-figure upfront

Acumen Pharmaceuticals, Inc.

Upfront payment in the seven-figure range for non-exclusive license to Halozyme's ENHANZE drug delivery technology.
Milestone payments tied to development/commercialization and net sales levels; single-digit royalties on worldwide net sales.
Halozyme named exclusive supplier of API for PH20 product for clinical and commercial supplies.
Agreement covers development of a subcutaneous formulation of ACU193.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Acumen Pharmaceuticals, Inc. entered into Non-exclusive Collaboration and License Agreement with Halozyme, Inc. valued at seven figure upfront payment (effective 2023-11-05).

Action: entry
Agreement: license
Counterparty: Halozyme, Inc.
Value: seven figure upfront payment
Effective: 2023-11-05

Exact text from the filing

On November 5, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Non-exclusive Collaboration and License Agreement (the “ Agreement ”) with Halozyme, Inc. (“ Halozyme ”).

View on SEC.gov

154 material agreements filed in the last 30 days. Browse all material agreements →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-23-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.